**MODEL B**

**TECHNICAL AND ECONOMIC DATA SHEET**

**OBJECT: SUPPLY OF COVID-19 VACCINES AND RELATED SERVICES FOR THE IMMUNISATION OF CITIZENS LIVING IN THE PIEDMONT REGION**

.

I, the undersigned \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ as (owner, legal representative, attorney, etc.) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ of the company: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ with registered office in (address)\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ VAT number \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**DISPOSE**

Of the following type(s) of Covid-19 vaccine, in quantities and at a target price

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **NR.** | **COMMERCIAL NAME** | **COUNTRY OF PRODUCTION** | **MAX QUANTITY AVAILABLE** | **TARGET UNIT PRICE IN €**  **(excluded VAT)** |
| 1 |  |  |  | € |
| 2 |  |  |  | € |

(*add lines as needed)*

With the following authorisations/documents:

1. **VACCINE NR. 1:**

□ EMA authorisation *(indicate references*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ AIFA authorisation *(indicate AIC*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Marketing authorisation application submitted to EMA (*indicate references*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Rolling review application submitted to EMA (*indicate references*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Other (*indicate authorisations held*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Estimated timeframe for acquisition of EMA authorisation \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **VACCINE NR. 2:**

□ EMA authorisation *(indicate references*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ AIFA authorisation *(indicate AIC*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Marketing authorisation application submitted to EMA (*indicate references*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Rolling review application submitted to EMA (*indicate references*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Other (*indicate authorisations held*) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

□ Estimated timeframe for acquisition of EMA authorisation \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**AND INDICATES**

a time schedule of the expected delivery times, compared to the maximum quantities available, during the duration of the supply (March-October 2021)

**VACCINE NR. 1:**

|  |  |
| --- | --- |
| **QUANTITIES (doses)** | **DELIVERY TIME** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

(*add lines as needed)*

1. **VACCINE NR. 2**

|  |  |
| --- | --- |
| **QUANTITIES (doses)** | **DELIVERY TIME** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

(*add line sas needed)*

**For each vaccine the relevant product technical data sheet is attached, which identifies the specific product to be quoted by the Economic Operator.**

Place and date

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

DECLARATOR SIGNATURE

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

***NOTA BENE***

* *The application must be accompanied by a photocopy, not authenticated, of a valid identity document of the subscriber(s).*